With more than a dozen development candidates, Humabs has a broad and varied pipeline of partnered, internal and public health programs. These anti-infective immunotherapy candidates are being developed to treat a number of viral and bacterial diseases.

Humabs has a successful track record of advancing its leads through the early stages of development.